Skip to contentA
Axim Biotechnologies, Inc.
A
AXIMAxim Biotechnologies, Inc. Q3 2023 · 10-Q
Revenue$9.58K$9.58K+629.1% vs Q3 2022 Net Income$328.47K$328.47KN/M vs Q3 2022 EPS Diluted$0.00$0.00N/M vs Q3 2022 Operating Income-$588,535N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Axim Biotechnologies, Inc. · CIK 1514946 · Engraved from SEC EDGAR
derived
Margins · derivedOperating margin-6142.7%+94155.6 pt vs Q3 2022
Net margin3428.3%+158264.5 pt vs Q3 2022
ended Sep 30, 2023 · filed Nov 20, 2023 · 51 d after period end